Articles
3 June 2009
Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005

Tumor idyotipe as target antigen for multiple myeloma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
157
Views
291
Downloads

Authors

Early during development, pre-B cells become committed to the expression of a heavy and light chain Ig variable region. The heavy chain derives from the recombination of a variable (V) with a diversity (D) and a joining (J) region genes with a constant region (C). The V-D-J joints occur with a variable number of nucleotide insertions or deletions resulting in a unique sequence which creates the third hypervariable region (CDR III) and contributes to the antigen binding site. These antigenic regions (idiotype; Id) are characteristic for any given Ig producing tumor (i.e. multiple myeloma, MM; non-Hodgkin lymphoma; NHL) and can be recognized by an immune response consisting of anti-Id antibodies and/or by Id reactive T-cells.

Altmetrics

Downloads

Citations

Supporting Agencies

How to Cite



Tumor idyotipe as target antigen for multiple myeloma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.286